Hutch News
Results per Page:
New Science Spotlight Articles
Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
September 18, 2023
Is the microbiome a springboard or barrier to effective vaccination?
From the Kublin Lab, Vaccine and Infectious Disease Division
Mosaic HIV immunogens boost the breadth of vaccine immune responses
From the Gilbert and McElrath Labs, Vaccine and Infectious Disease Division
Immune signature reveals new therapeutic potential in colon cancer
From Dr. Jeroen Huyghe and the Peters Lab, Public Health Sciences Division
One gene, two functions in bacterial immunity
From the Stoddard Lab, Basic Sciences Division and the Kaiser Lab, Seattle University
Accepting glowing cells as one’s own allows immune competent metastatic studies
From the Ghajar Lab, Public Health Sciences and Human Biology Divisions
How the Gale Lab “RIG”s innate immune responses against hepatitis B
From the Gale Lab, Pathogen Associated Malignancies Program, Cancer Consortium
Fred Hutch at CROI: COVID-19 vaccine efficacy trials, T-cell immunity following vaccination, immune responses to SARS-CoV-2, and late-breaking science on HPV, HIV and long-term antiretroviral therapy
Conference on Retroviruses and Opportunistic Infections to be held virtually March 6 – 10, 2021
After chemotherapy, immune system recovery may be slower than believed
<p>Chemo weakens the immune system for up to nine months, especially in smokers, one study finds</p>
Patient's own infection-fighting T cells put late-stage melanoma into long-term remission — without chemotherapy or radiation
Case is first to show safety and effectiveness of using cloned cells alone to kill tumors